Stifel Nicolaus Reaffirms Their Hold Rating on Teladoc (TDOC)

In a report released today, David Grossman from Stifel Nicolaus maintained a Hold rating on Teladoc (TDOC – Research Report), with a price target of $16.00. The company’s shares closed yesterday at $13.33.

According to TipRanks, Grossman is a 4-star analyst with an average return of 8.6% and a 58.33% success rate. Grossman covers the Technology sector, focusing on stocks such as Accenture, Epam Systems, and Infosys.

In addition to Stifel Nicolaus, Teladoc also received a Hold from Truist Financial’s Jailendra Singh in a report issued today. However, on the same day, Piper Sandler maintained a Buy rating on Teladoc (NYSE: TDOC).

The company has a one-year high of $30.41 and a one-year low of $12.86. Currently, Teladoc has an average volume of 4.85M.

Based on the recent corporate insider activity of 79 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TDOC in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Teladoc (TDOC) Company Description:

Teladoc Health, Inc. is a multinational telemedicine and virtual healthcare company. The company provides telehealth solutions, expert medical services, medical opinions, artificial intelligence and analytics, behavioral health solutions, guidance and support, and platform and program services.